Elevated CD8 counts during HAART are associated with HIV virologic treatment failure

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 5, 2011, Pages 396-403

  Krantz, Elizabeth M ^a,b   Hullsiek, Katherine Huppler ^a,b   Okulicz, Jason F ^a,c   Weintrob, Amy C ^a,d   Agan, Brian K ^a   Crum Cianflone, Nancy F ^a,e   Ganesan, Anuradha ^a,d   Ferguson, Tomas M ^a,f   Hale, Braden R ^e  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

antiretroviral therapy; CD8 count; HIV viral load suppression; HIV virologic failure; human immunodeficiency virus

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 80051548189     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318221c62a     Document Type: Article

References (58)

1. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Response to combination antiretroviral therapy: variation by age. AIDS. 2008;22:1463-1473.
2. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35-F43. (Pubitemid 29286695)
3. Hartzell JD, Spooner K, Howard R, et al. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy in a military cohort despite equal access to care. J Acquir Immune Defic Syndr. 2007;44:411-416. (Pubitemid 46555375)
4. Lederberger B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353:863-868. (Pubitemid 29126872)
5. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87. (Pubitemid 29340558)
6. Mocroft A, Gill MJ, Davidson W, et al. Predictors of a viral response and subsequent virological treatment failure in patients starting a protease inhibitor. AIDS. 1998;12:2161-2167. (Pubitemid 28495270)
7. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med. 2000;160:1123-1132. (Pubitemid 30227022)
8. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2560-2567. (Pubitemid 33096807)
9. Weintrob AC, Grandits GA, Agan BK, et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009;52:574-580.
10. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1 infected patients initiating a protease inhibitor-containing regimen. AIDS. 2002;16:21-29. (Pubitemid 34062178)
11. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003;17:1741-1751. (Pubitemid 37000092)
12. Phillips AN, Staszewski S, Lampe F, et al. Human immunodeficiency virus rebound after suppression to ,400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. Infect Dis. 2002;186:1086-1091. (Pubitemid 35177110)
13. Robbins GK, Daniels B, Zheng H, et al. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr. 2007;44:30-37. (Pubitemid 46052217)
14. Robbins GK, Johnson KL, Chang Y, et al. Predicting virologic failure in an HIV clinic. Clin Infect Dis. 2010;50:779-786.
15. Ramirez-Amador V, Ponce-de-Leon S, Anaya-Saavedra G, et al. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City. Clin Infect Dis. 2007;45: 925-932. (Pubitemid 47580390)
16. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231-241. (Pubitemid 351160160)
17. Silvestri G. Naturally SIV-infected sooty mangabeys: are we closer to understanding why they do not develop AIDS? J Med Primatol. 2005;34: 243-252. (Pubitemid 41179586)
18. Saksena NK, Wu JQ, Potter SJ, et al. Human immunodeficiency virus interactions with CD8+ T Lymphocytes. Curr HIV Res. 2008;6:1-9. (Pubitemid 351461015)
19. Walker CM, Erickson AL, Hsueh FC, et al. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxicmechanism. J Virol. 1991;65:5921-5927.
20. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today. 1996;17:217-224. (Pubitemid 26148565)
21. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 2001;22:312-316. (Pubitemid 32675244)
22. Levy JA. The search for the CD8+ cell anti-HIV factor (CAF). Trends Immunol. 2003;24:628-632. (Pubitemid 37485911)
23. Ferbas J, Kaplan AH, Hausner MA, et al. Virus burden in long-term survivors of Human Immunodeficiency (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. Infect Dis. 1995;172:329-339.
24. Gomez AM, Smaill FM, Rosenthal KL. Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease. Clin Exp Immunol. 1994;97:68-75. (Pubitemid 24244057)
25. Mackewicz CE, Ortega HW, Levy JA. CD8+ cell anti-HIV activity correlates with the clinical state of the individual. J Clin Invest. 1991;87: 1462-1466.
26. Landay AL, Mackewicz CE, Levy JA. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol. 1993;69:106-116. (Pubitemid 23303584)
27. Barker E, Mackewicz CE, Reyes-Teran G, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood. 1998; 92:3105-3114. (Pubitemid 28492316)
28. Castelli JC, Deeks SG, Shiboski S, et al. Relationship of CD8+ T cell noncytotoxic anti-HIV response to CD4+ T cell number in untreated asymptomatic HIV-infected individuals. Blood. 2002;99:4225-4227. (Pubitemid 35332071)
29. Killian MS, Johnson C, Teque F, et al. Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. J Virol. 2011;85:1696-1705.
30. Hazenberg MD, Otto SA, van Benthem BHB, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881-1888. (Pubitemid 37070273)
31. Doitsh G, Cavrois M, Lassen KG, et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell. 2010;143:789-801.
32. Bofill M, Mocroft A, Lipman M, et al. Increased numbers of primed activated CD8+ CD38+ CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1 infected patients. AIDS. 1996;10:827-834.
33. Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr. 1993;6:904-912. (Pubitemid 23207458)
34. Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations if HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83-92.
35. Perfetto SP, Malone JD, Hawkes C, et al. CD38 expression on cryopreserved CD8+ T cells predicts disease progression. Cytometry. 1998;33:133-137. (Pubitemid 28447137)
36. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. Infect Dis. 2003;187:1534-1543. (Pubitemid 36578959)
37. Benito JM, Lopez M, Lozano S, et al. CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation. Infect Dis. 2005;192:2142-2146. (Pubitemid 41779214)
38. Ondoa P, Koblavi-Deme S, Borget MY, et al. Assessment of CD8+ T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Cote d'Ivoire. Clin Exp Immunol. 2005; 140:138-148. (Pubitemid 40461083)
39. Onlamoon N, Tabprasit S, Suwanagool S, et al. Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1 infected patients in Thailand. Virology. 2005;341:238-248.
40. Steel A, John L, Shamji MH, et al. CD38 expression on CD8 T cells has aweak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1 infected patients on antiretroviral therapy. HIV Med. 2008;9:118-125. (Pubitemid 351228135)
41. Appay V, Almeida JR, Sauce D, et al. Accelerated immune senescence and HIV-1 infection. Exp Gerontol. 2007;42:432-437. (Pubitemid 46561182)
42. Hazenberg MD, Stuart JWTC, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection ismainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood. 2000;95:249-255. (Pubitemid 30017249)
43. Adleman LM, Wofsy D. T-cell homeostasis: implications in HIV infection. J Acquir Immune Defic Syndr. 1993;6:144-152. (Pubitemid 23082868)
44. Anderson RE, Shiboski SC, Royce R, et al. CD8+ T lymphocytes and progression to AIDS in HIV-infected men: some observations. AIDS. 1991;5:213-215.
45. Phillips AN, Sabin CA, Elford J, et al. CD8 lymphocytes and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up. AIDS. 1993;7: 975-980. (Pubitemid 23239672)
46. Schechter MT, Craib KJP, Le TN, et al. Susceptibility to AIDS progression appears early in HIV infection. AIDS. 1990;4:185-190. (Pubitemid 20146994)
47. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-172. (Pubitemid 20036390)
48. Chevret S, Roquin H, Ganne P, et al. Prognostic value of an elevated CD8 lymphocyte count in HIV infection. Results of a prospective study of 152 asymptomatic HIV-positive individuals. AIDS. 1992;6:1349-1352.
49. Weintrob AC, Fieberg AM, Agan BK, et al. Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr. 2008;49:40-47.
50. Marconi VC, Grandits GA,Weintrob AC, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther. 2010;7:14.
51. Wolfe WH, Miner JC, Michalek JE. Immunological parameters in current and former US Air Force personnel. Vaccine. 1993;11:545-547. (Pubitemid 23130862)
52. Backteman K, Ernerudh J. Biological and methodological variation of lymphocyte subsets in blood of human adults. J Immunol Meth. 2007;322: 20-27. (Pubitemid 46560577)
53. Aldous JL, Haubrich RH. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS. 2009;4:459-466.
54. Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood. 2010; prepublished online.
55. Hull MW, Lima VD, Hogg RS, et al. Epidemiology of treatment failure: a focus on recent trends. Curr Opin HIV AIDS. 2009;4:467-473.
56. Vo TTN, Ledergerber B, Keiser O, et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort study. Infect Dis. 2008;197:1685-1694. (Pubitemid 351919632)
57. Reekie J, Mocroft A, Sambatakou H, et al. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS. 2008;22:2381-2390.
58. Smith CJ, Phillips AN, Hill T, et al. The rate of viral rebound after attainment of an HIV load >50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. Infect Dis. 2005;192:1387-1397 (Pubitemid 41401152)